Citadel Advisors - RECURSION PHARMACEUTICALS IN ownership

RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 129 filers reported holding RECURSION PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is 1.41 and the average weighting 1.8%.

Quarter-by-quarter ownership
Citadel Advisors ownership history of RECURSION PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$3,559,469
-38.2%
465,290
-39.6%
0.00%
-100.0%
Q2 2023$5,757,562
+32.7%
770,758
+18.4%
0.00%0.0%
Q1 2023$4,340,269
-28.9%
650,715
-17.8%
0.00%0.0%
Q4 2022$6,102,851
+7.8%
791,550
+48.7%
0.00%0.0%
Q3 2022$5,663,000
+98.0%
532,370
+51.5%
0.00%0.0%
Q2 2022$2,860,000
-57.1%
351,372
-62.3%
0.00%0.0%
Q1 2022$6,666,000
+79.3%
931,070
+329.1%
0.00%0.0%
Q4 2021$3,718,000
+327.4%
217,007
+474.1%
0.00%
Q3 2021$870,000
+278.3%
37,800
+500.0%
0.00%
Q2 2021$230,0006,3000.00%
Other shareholders
RECURSION PHARMACEUTICALS IN shareholders Q1 2022
NameSharesValueWeighting ↓
Obvious Management Services, L.L.C. 3,985,087$42,401,000100.00%
Two Sigma Ventures, LP 903,400$9,612,000100.00%
DCVC Opportunity Fund II GP, LLC 3,951,141$42,040,00054.37%
Data Collective IV GP, LLC 5,941,120$63,214,00049.97%
MIC Capital Management UK LLP 8,451,758$89,927,00016.21%
MV Management XI, L.L.C. 1,971,908$20,981,00015.20%
ArchPoint Investors 1,116,126$11,876,0004.85%
HARVARD MANAGEMENT CO INC 1,509,254$16,058,0002.00%
PLATINUM INVESTMENT MANAGEMENT LTD 2,251,971$23,961,0001.00%
Duquesne Family Office 1,385,950$14,747,0000.84%
View complete list of RECURSION PHARMACEUTICALS IN shareholders